Robert Wenham, MD
Gynecologic Oncology · Tampa, FLNPI 1295740645
Payments from drug & device makers
Across 404 payments — averaging $7235.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$984K
- Eisai Inc.$749K
- Regeneron$539K
- AstraZeneca$209K
- Iovance Biotherapeutics, Inc.$190K
- Takeda Pharmaceuticals U.S.A., Inc.$66K
- plus $188K from 17 others
Across 1 payment — averaging $113.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$114
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $983,854 |
| Eisai Inc. | 95 | $748,508 |
| Regeneron | 71 | $538,665 |
| AstraZeneca | 11 | $208,660 |
| Iovance Biotherapeutics, Inc. | 40 | $189,935 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $65,669 |
| Janssen Research & Development, LLC | 2 | $35,854 |
| Springworks Therapeutics, Inc. | 36 | $32,300 |
| Clovis Oncology, Inc. | 24 | $26,384 |
| E.r. Squibb & Sons, L.L.C. | 2 | $16,307 |
| Tesaro, Inc. | 18 | $16,021 |
| GSK | 9 | $14,791 |
| Acerta Pharma LLC | 2 | $14,474 |
| Seagen Inc. | 6 | $6,453 |
| Corcept Therapeutics | 7 | $6,204 |
| Genentech USA, Inc. | 6 | $6,129 |
| AbbVie | 15 | $4,690 |
| On Target Laboratories, Inc | 2 | $3,795 |
| Pfizer | 3 | $2,990 |
| Genmab U.S., Inc. | 3 | $1,068 |
| Baxter Healthcare | 6 | $271 |
| Foundation Medicine, Inc. | 1 | $96 |
| Medtronic | 1 | $54 |
How this compares
$2,923,172 in reported general payments places this provider in the 95th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Tampa
- Hye Sook ChonTampa$2.4M
- Vaagn AndikyanTampa$279K
- Mian ShahzadTampa$131K
- Jing-Yi ChernTampa$44K
- Thomas RutherfordTampa$6K
- Matthew SchlumbrechtMiami$16.7M
- Brian SlomovitzFort Lauderdale$13.9M
- Bradley MonkWest Palm Beach$10.5M
- John DiazMiami$3.7M
- Robert HollowayOrlando$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.